| Literature DB >> 25552469 |
Nina E Hasselberg1, Kristina H Haugaa1, Sebastian I Sarvari1, Lars Gullestad2, Arne K Andreassen3, Otto A Smiseth1, Thor Edvardsen4.
Abstract
AIMS: Heart failure patients with reduced and preserved left ventricular (LV) ejection fraction (EF) show reduced exercise capacity. We explored the relationship between exercise capacity and systolic and diastolic myocardial function in heart failure patients. METHODS ANDEntities:
Keywords: diastolic function; exercise testing; heart failure; myocardial mechanics; speckle tracking echocardiography
Mesh:
Year: 2014 PMID: 25552469 PMCID: PMC4307775 DOI: 10.1093/ehjci/jeu277
Source DB: PubMed Journal: Eur Heart J Cardiovasc Imaging ISSN: 2047-2404 Impact factor: 6.875
Patient characteristics
| Total study population ( | Patients with HFpEF ( | |
|---|---|---|
| Age (years) | 56 ± 12 | 58 ± 11 |
| Gender (male/female) ( | 73/27 | 25/12 |
| HR (bpm) | 74 ± 15 | 77 ± 16 |
| Systolic BP (mmHg) | 116 ± 26 | 135 ± 21 |
| Diastolic BP (mmHg) | 71 ± 14 | 79 ± 11 |
| BMI (kg/m2) | 26 ± 4 | 26 ± 4 |
| NYHA class | 2.5 ± 0.9 | 2.0 ± 0.5 |
| Diabetes ( | 13 (13%) | 5 (14%) |
| Hypertension ( | 25 (25%) | 15 (41%) |
| NT-proBNP (pmol/L) ( | 464 ± 612 | 115 ± 164 |
| Aetiology of heart failure | ||
| Ischaemic heart disease ( | 47 (47%) | 22 (60%) |
| Dilated CM ( | 34 (34%) | 0 |
| Hypertrophic CM ( | 3 (3%) | 2 (5%) |
| CM from hypertension, diabetes, and other ( | 16 (16%) | 13 (35%) |
| CPX parameters | ||
| Peak exercise (Watt) | 102 ± 62 | 136 ± 59 |
| Peak exercise (METs) | 4.4 ± 1.8 | 5.7 ± 2.0 |
| HR at peak exercise (bpm) | 125 ± 25 | 133 ± 20 |
| Systolic BP at peak exercise (mmHg) | 154 ± 49 | 187 ± 34 |
| Diastolic BP at peak exercise (mmHg) | 84 ± 30 | 92 ± 21 |
| Peak VO2 (mL/kg/min) | 15.4 ± 6.3 | 20.1 ± 6.9 |
| VE/VCO2 ( | 30.7 ± 7.8 | 26.1 ± 4.0 |
| Echocardiographic parameters | ||
| LV ESV index (mL/m2) | 49 ± 44 | 14 ± 5 |
| LV EDD index (mm/m2) | 32 ± 7 | 26 ± 2 |
| LV EF (%) | 42 ± 19 | 62 ± 7 |
| LV GLS (%) | −11.9 ± 6.6 | −17.5 ± 3.2 |
| TAPSE (cm) | 1.6 ± 0.9 | 1.8 ± 0.6 |
| RV S′ (cm/s) | 8.6 ± 3.3 | 9.4 ± 3.1 |
| Peak PASP (mmHg) | 38 ± 13 | 31 ± 10 |
| RV FAC (%) | 37 ± 14 | 48 ± 11 |
| RV strain (%) | −14.9 ± 6.5 | −22.8 ± 5.7 |
| | 78 ± 28 | 72 ± 23 |
| | 206 ± 76 | 245 ± 75 |
| | 1.97 ± 1.30 | 1.53 ± 1.08 |
| | 5.8 ± 2.5 | 7.1 ± 2.0 |
| | 17 ± 12 | 11 ± 5 |
| Left atrial area (cm2) | 28.1 ± 9.0 | 24.4 ± 7.4 |
| Left atrial volume index (mL/m2) | 56 ± 26 | 45 ± 22 |
A, late diastolic filling velocity; BMI, body mass index; BP, arterial blood pressure; bpm, beats per minute; CM, cardiomyopathy; CPX, cardiopulmonary exercise testing; E, peak early diastolic filling velocity; e′, early diastolic mitral annular velocity(septal); EDD, end diastolic diameter; EF, ejection fraction; ESV, end systolic volume; FAC, fractional area change; GLS, global longitudinal strain; HFpEF, heart failure with preserved ejection fraction; HR, heart rate; LV, left ventricular; METs, metabolic equivalents; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PASP, pulmonary arterial systolic pressure; RV, right ventricular; S′, tricuspid lateral annular systolic velocity; TAPSE, tricuspid annular plane systolic excursion; VE/VCO2, minute ventilation/carbon dioxide production; VO2, oxygen uptake.
Univariate (R) and multivariate analyses (β) of correlations between exercise capacity by peak VO2 and clinical and echocardiographic parameters in the total study population (left) and the HFpEF patients (right)
| Relation to peak VO2 | Total study population ( | Patients with HFpEF ( | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate correlation | Multivariate regression | Univariate correlation | Multivariate regression | |||||
| Age, per 5 years | 0.13 | 0.20 | −0.37 (−0.85 to 0.12) | 0.13 | −0.01 | 0.99 | −1.07 (−2.07 to −0.07) | 0.04 |
| NYHA class | −0.77 | <0.001 | −0.65 | <0.001 | ||||
| NT-proBNP, per 10 pmol/L | −0.35 | 0.002 | −0.02 (−0.04 to 0.01) | 0.25 | −0.47 | 0.02 | ||
| LV EDD index | −0.43 | <0.001 | 0.08 (−0.16 to 0.33) | 0.50 | 0.12 | 0.48 | ||
| LV EF | 0.62 | <0.001 | −0.01 (−0.13 to 0.11) | 0.87 | 0.08 | 0.62 | ||
| LV GLS | −0.63 | <0.001 | −0.42 (−0.79 to −0.04) | 0.03 | −0.50 | 0.002 | −0.80 (−1.49 to −0.11) | 0.02 |
| TAPSE | 0.27 | 0.008 | 0.39 (−1.18 to 1.96) | 0.62 | 0.49 | 0.003 | ||
| RV S′ | 0.33 | 0.001 | 0.02 (−0.34 to 0.38) | 0.92 | 0.35 | 0.04 | 0.54 (−0.10 to 1.19) | 0.09 |
| Peak PASP | −0.55 | <0.001 | −0.15 (−0.28 to −0.02) | 0.02 | −0.49 | 0.002 | −0.35 (−0.68 to −0.02) | 0.04 |
| RV FAC | 0.54 | <0.001 | 0.35 | 0.03 | 0.08 (−0.11 to 0.28) | 0.38 | ||
| RV strain | −0.50 | <0.001 | −0.34 | 0.05 | ||||
| −0.28 | 0.04 | −0.39 | 0.02 | |||||
| 0.48 | <0.001 | 0.34 | 0.04 | |||||
| −0.43 | <0.001 | −0.26 | 0.13 | |||||
| 0.46 | <0.001 | 0.20 | 0.24 | |||||
| −0.41 | <0.001 | 0.06 (−0.05 to 0.18) | 0.28 | −0.43 | 0.008 | 0.12 (−0.44 to 0.69) | 0.66 | |
| Left atrial area | −0.40 | <0.001 | −0.28 | 0.09 | ||||
| Left atrial volume index | −0.41 | <0.001 | −0.03 (−0.08 to 0.02) | 0.16 | −0.28 | 0.09 | ||
A, late diastolic filling velocity; β, beta regression coefficient; CI, confidence interval; E, peak early diastolic filling velocity; e′, early diastolic mitral annular velocity(septal); EDD, end diastolic diameter; EF, ejection fraction; FAC, fractional area change; GLS, global longitudinal strain; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PASP, pulmonary arterial systolic pressure; R, Pearson coefficient; RV, right ventricular; S′, tricuspid lateral annular systolic velocity; TAPSE, tricuspid annular plane systolic excursion; VO2, oxygen uptake.